Balancing nutrition and serum phosphorus in maintenance dialysis

American Journal of Kidney Diseases

Volumn 64, Issue 1, 2014, Pages 143-150

  Fouque, Denis ^a   Horne, Rob ^b   Cozzolino, Mario ^c   Kalantar Zadeh, Kamyar ^d,e  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

chronic kidney disease; Diet, protein restricted; Index Words; phosphate binders; phosphorus, dietary

Indexed keywords

ALBUMIN; CALCIFEDIOL; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; COLECALCIFEROL; FIBROBLAST GROWTH FACTOR 23; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER CARBONATE;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CALORIC INTAKE; CASE REPORT; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DRUG USE; END STAGE RENAL DISEASE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LIFESTYLE; MAINTENANCE THERAPY; MALE; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); MIDDLE AGED; MORTALITY; NUTRITION; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROTEIN INTAKE; PROTEIN RESTRICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY HYPERPARATHYROIDISM; SYSTEMATIC REVIEW (TOPIC);

CHRONIC KIDNEY DISEASE; DIET, PROTEIN-RESTRICTED; PHOSPHATE BINDERS; PHOSPHORUS, DIETARY;

DIET, PROTEIN-RESTRICTED; DIETARY PROTEINS; DISEASE MANAGEMENT; HUMANS; MALE; MIDDLE AGED; NUTRITION THERAPY; PHOSPHATE-BINDING PROTEINS; PHOSPHORUS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84903276088     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.01.429     Document Type: Article

References (42)

1. D. Fouque, H. Roth, and S. Pelletier et al. Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets? Nephrol Dial Transplant 28 2013 360 367
2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int Suppl 113 2009 S1 S130
3. D. Fouque, and M. Aparicio Eleven reasons to control the protein intake of patients with chronic kidney disease Nat Clin Pract Nephrol 3 7 2007 383 392
4. National Kidney Foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure Am J Kidney Dis 35 suppl 2 2000 S1 S140
5. C.S. Shinaberger, S. Greenland, and J.D. Kopple et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr 88 6 2008 1511 1518
6. National Kidney Foundation K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease Am J Kidney Dis 42 4 suppl 3 2003 S1 S201
7. D. Fouque, M. Vennegoor, and P. ter Wee et al. EBPG guideline on nutrition Nephrol Dial Transplant 22 suppl 2 2007 ii45 ii87
8. K. Kalantar-Zadeh, L. Gutekunst, and R. Mehrotra et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease Clin J Am Soc Nephrol 5 3 2010 519 530
9. D. Fouque, K. Kalantar-Zadeh, and J. Kopple et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease Kidney Int 73 4 2008 391 398
10. G. Barsotti, A. Cupisti, and E. Morelli et al. Secondary hyperparathyroidism in severe chronic renal failure is corrected by very-low dietary phosphate intake and calcium carbonate supplementation Nephron 79 2 1998 137 141
11. S.M. Moe, M.P. Zidehsarai, and M.A. Chambers et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease Clin J Am Soc Nephrol 6 2 2011 257 264
12. A. Cupisti, F. Comar, and O. Benini et al. Effect of boiling on dietary phosphate and nitrogen intake J Ren Nutr 16 1 2006 36 40
13. J. Uribarri, and M.S. Calvo Hidden sources of phosphorus in the typical American diet: does it matter in nephrology? Semin Dial 16 3 2003 186 188
14. O. Benini, C. D'Alessandro, D. Gianfaldoni, and A. Cupisti Extra-phosphate load from food additives in commonly eaten foods: a real and insidious danger for renal patients J Ren Nutr 21 4 2011 303 308
15. L. Murphy-Gutekunst Hidden phosphorus in popular beverages: part 1 J Ren Nutr 15 2 2005 e1 e6
16. C.S. Shinaberger, R.D. Kilpatrick, and D.L. Regidor et al. Longitudinal associations between dietary protein intake and survival in hemodialysis patients Am J Kidney Dis 48 1 2006 37 49
17. K.E. Lynch, R. Lynch, G.C. Curhan, and S.M. Brunelli Prescribed dietary phosphate restriction and survival among hemodialysis patients Clin J Am Soc Nephrol 6 3 2011 620 629
18. A.A. Lopes, L. Tong, and J. Thumma et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status Am J Kidney Dis 60 1 2012 90 101
19. Copley B, Heise J, Isnard-Bagnis C. High-capacity phosphate binder for the dialysis population: potential to support improvements in dietary protein intake with a low tablet burden. Poster presented at: World Congress of Nephrology, May 31-June 4, 2013; Hong Kong.
20. M. Cozzolino, S. Mazzaferro, and V. Brandenburg The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders? Nephrol Dial Transplant 26 2 2011 402 407
21. D.J. Goldsmith, A. Covic, and D. Fouque et al. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement Nephrol Dial Transplant 25 12 2010 3823 3831
22. S.A. Jamal, B. Vandermeer, and P. Raggi et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis Lancet 382 9900 2013 1268 1277
23. P. Ciceri, E. Volpi, and I. Brenna et al. The combination of lanthanum chloride and the calcimimetic calindol delays the progression of vascular smooth muscle cells calcification Biochem Biophys Res Commun 418 4 2012 770 773
24. I.G. Nikolov, N. Joki, and T. Nguyen-Khoa et al. Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice Nephrol Dial Transplant 27 2 2012 505 513
25. G.A. Block, D.M. Spiegel, and J. Ehrlich et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis Kidney Int 68 4 2005 1815 1824
26. N.D. Toussaint, K.K. Lau, K.R. Polkinghorne, and P.G. Kerr Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial Nephrology (Carlton) 16 3 2011 290 298
27. R.S. Kalil, M. Flanigan, W. Stanford, and W.G. Haynes Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study Clin Nephrol 78 1 2012 1 9
28. P. Urena, S.H. Jacobson, and E. Zitt et al. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice - the ECHO observational study Nephrol Dial Transplant 24 9 2009 2852 2859
29. E. Zitt, M. Rix, and P. Urena Torres et al. Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study Nephrol Dial Transplant 26 6 2011 1956 1961
30. E. Zitt, D. Fouque, and S.H. Jacobson et al. Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction Clin Kidney J 6 3 2013 287 294
31. J. Cunningham, M. Danese, K. Olson, P. Klassen, and G.M. Chertow Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism Kidney Int 68 4 2005 1793 1800
32. P. Raggi, G.M. Chertow, and P.U. Torres et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis Nephrol Dial Transplant 26 4 2011 1327 1339
33. G.M. Chertow, G.A. Block, and R. Correa-Rotter et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis N Engl J Med 367 26 2012 2482 2494
34. O. Gutiérrez, M. Mannstadt, and T. Isakova et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis N Engl J Med 359 2008 584 592
35. T. Shigematsu, S. Negi, and C.R. Group Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study) Nephrol Dial Transplant 27 3 2012 1050 1054
36. M.I. Yilmaz, A. Sonmez, and M. Saglam et al. Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial Am J Kidney Dis 59 2 2012 177 185
37. C. Karamanidou, J. Clatworthy, J. Weinman, and R. Horne A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease BMC Nephrol 9 2008 2
38. R. Horne Compliance, adherence and concordance K. Taylor, G. Harding, Pharmacy Practice 2001 Taylor and Francis London, United Kingdom 165 184
39. T. Ahlenstiel, L. Pape, J.H. Ehrich, and M.K. Kuhlmann Self-adjustment of phosphate binder dose to meal phosphorus content improves management of hyperphosphataemia in children with chronic kidney disease Nephrol Dial Transplant 25 2010 3241 3249
40. V. Wileman, J. Chilcot, S. Norton, L. Hughes, D. Wellsted, and K. Farrington Choosing not to take phosphate binders: the role of dialysis patients' medication beliefs Nephron Clin Pract 119 3 2011 c205 c213
41. R. Horne, and J. Weinman Self regulation and self management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication Psychol Health 17 2002 17 32
42. J.T. Daugirdas, W.F. Finn, M. Emmett, and G.M. Chertow The phosphate binder equivalent dose Semin Dial 24 1 2011 41 49